Chardan raised the firm's price target on Editas Medicine to $4 from $3.50 and keeps a Buy rating on the shares following the Q1 report. Editas reaffirmed key EDIT-401 milestones, the analyst tells investors in a research note. Chardan sees a favorable backdrop for EDIT-401's development.
